Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action
Mario Eisenberger, Menachem Laufer, Nicholas J. Vogelzang, Oliver Sartor, Donald Thornton, Blake Lee Neubauer, Victoria Sinibaldi, Gary Lieskovsky, Michael A. Carducci, Mariana Zahurak, Derek Raghavan
Dive into the research topics of 'Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action'. Together they form a unique fingerprint.